PIQUR Therapeutics AG

About PIQUR Therapeutics AG

PIQUR was founded in August 2011 by Vladimir Cmiljanovic, Bernd Giese, Matthias Wymann, Andreas Emmenegger and Ralf Rosenow as a spin-off of the University of Basel. The company focuses on the discovery and development of innovative anti-cancer drugs based on the inhibition of the PI3K (phosphoinositide 3-kinase) and mTOR (mammalian target of rapamycin) pathways, one of the most promising research areas in oncology and clinically validated drug targets. PIQUR’s lead candidate, PQR309, has successfully concluded the first Phase 1 trial. The initial results indicate that PQR309 is well-tolerated with no significant side effects and meets the primary endpoints of safety and tolerability. Furthermore, PQR309 demonstrated clear biologic activity and first promising signs of clinical activity. In Q2/2015, PIQUR has started Phase 2 trials with PQR309 in selected cancer indications.
YEAR FOUNDED:
August 2011
LEADERSHIP:
CEO: Vladimir Cmiljanovic
CMO:Melanie Rolli
CSO: Doriano Fabbro
CBO: Hervé Girsault
CFO: Martin Gasser
JOBS:
Please click here for PIQUR job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.